Financial Results for the quarter and year ended 31st March, 2026

Pat NegativeEbitda Margin CompressionExceptional ItemEmphasis Of MatterResults View source PDF

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.3%1-day move

₹540.00

prior close

₹513.70

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.6+3.6+4.0+3.3-4.3-4.8-3.7-5.1-3.1-3.5+2.4+14.6+27.2—

Up moveDown movePending

AI summary

Akums Drugs and Pharmaceuticals reported FY26 standalone revenue of ₹13,487 million, up just 2.8% from ₹13,118 million in FY25. Profit after tax fell sharply to ₹1,116 million from ₹1,610 million — a decline of about 31% year-on-year. EBITDA margin compressed significantly to ~10% from ~14.5% previously. The company recognized ₹65.19 million in exceptional items comprising ₹52.32 million for changes under new labour codes and ₹12.87 million for retrospective VDA arrears. Auditors Walker Chandiok & Co. LLP issued an unmodified opinion but included an Emphasis of Matter regarding an Income Tax Department search and seizure operation conducted in January 2025; the company has received show cause notices and the financial impact remains unascertained. The board recommended a final dividend of ₹1 and a special dividend of ₹2 per share.

Likely market impact

The sharp PAT decline and margin compression are concerning signals despite flat revenue growth. The ongoing Income Tax Department proceedings add regulatory uncertainty. The dividend payout provides some investor comfort.